599 related articles for article (PubMed ID: 32966047)
1. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
2. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.
Bocanegra Gondan AI; Ruiz-de-Angulo A; Zabaleta A; Gómez Blanco N; Cobaleda-Siles BM; García-Granda MJ; Padro D; Llop J; Arnaiz B; Gato M; Escors D; Mareque-Rivas JC
Biomaterials; 2018 Jul; 170():95-115. PubMed ID: 29656235
[TBL] [Abstract][Full Text] [Related]
3. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor agonists in cancer therapy.
Adams S
Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy.
Ohadian Moghadam S; Nowroozi MR
Scand J Immunol; 2019 Dec; 90(6):e12818. PubMed ID: 31448424
[TBL] [Abstract][Full Text] [Related]
7. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines.
Mitchell D; Yong M; Raju J; Willemsen N; Black M; Trent A; Tirrell M; Olive C
Hum Vaccin; 2011; 7 Suppl():85-93. PubMed ID: 21245658
[TBL] [Abstract][Full Text] [Related]
9. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
Corogeanu D; Zaki K; Beavil AJ; Arnold JN; Diebold SS
PLoS One; 2023; 18(3):e0282831. PubMed ID: 36913398
[TBL] [Abstract][Full Text] [Related]
10. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists.
Bourquin C; Pommier A; Hotz C
Pharmacol Res; 2020 Apr; 154():104192. PubMed ID: 30836160
[TBL] [Abstract][Full Text] [Related]
12. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
13. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
14. Biomaterials as Local Niches for Immunomodulation.
Adu-Berchie K; Mooney DJ
Acc Chem Res; 2020 Sep; 53(9):1749-1760. PubMed ID: 32786230
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer.
Haegebaert RMS; Kempers M; Ceelen W; Lentacker I; Remaut K
Eur J Pharm Biopharm; 2022 Mar; 172():16-30. PubMed ID: 35074555
[TBL] [Abstract][Full Text] [Related]
16. Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation.
Mottas I; Bekdemir A; Cereghetti A; Spagnuolo L; Yang YS; Müller M; Irvine DJ; Stellacci F; Bourquin C
Biomaterials; 2019 Jan; 190-191():111-120. PubMed ID: 30415018
[TBL] [Abstract][Full Text] [Related]
17. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the Microbiome to Enhance Cancer Immunotherapy.
Nelson MH; Diven MA; Huff LW; Paulos CM
J Immunol Res; 2015; 2015():368736. PubMed ID: 26101781
[TBL] [Abstract][Full Text] [Related]
19. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.
Wittig B; Schmidt M; Scheithauer W; Schmoll HJ
Crit Rev Oncol Hematol; 2015 Apr; 94(1):31-44. PubMed ID: 25577571
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.
Nuhn L; De Koker S; Van Lint S; Zhong Z; Catani JP; Combes F; Deswarte K; Li Y; Lambrecht BN; Lienenklaus S; Sanders NN; David SA; Tavernier J; De Geest BG
Adv Mater; 2018 Nov; 30(45):e1803397. PubMed ID: 30276880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]